Friday, October 31, 2014

Tuesday Features

AD focus shifts to treating agitation/aggression

AD focus shifts to treating agitation/aggression

After years of fruitless search for new therapies to slow the deadly progression of Alzheimer’s disease (AD), researchers are having more success with experimental treatments for the neuropsychiatric symptoms associated with AD, such as agitation and aggression. A case in point is Avanir Pharmaceuticals (NASDAQ:AVNR), which reported positive results... [Read more of this feature]


Stellar Biotechnologies harvests mollusks for KLH protein

Stellar Biotechnologies harvests mollusks for KLH protein

A mollusk living in the coastal waters off California from Monterey to the Baja Peninsula may hold the key to new therapies to treat cancer and autoimmune diseases. Frank Oakes Stellar Biotechnologies (OTCQB:SBOTF; TSX-V:KLH) has pioneered technology to grow the mollusk, known as the Giant Keyhole Limpet, and produce and purify KLH, or keyhole limpet... [Read more of this feature]


In conversation with Ron Babecoff

In conversation with Ron Babecoff

Ron Babecoff As a co-founder of BiondVax Pharmaceuticals (TASE:BNDX), Ron Babecoff has led the Israeli developer of a universal flu vaccine since its inception in 2003. Prior to BiondVax, Dr. Babecoff was with Omrix Biopharmaceuticals as marketing manager, where he was involved in identifying West Nile Fever treatments and building cooperation with... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Novadaq to obtain SPY Elite rights from LifeCell

Novadaq to obtain SPY Elite rights from LifeCell

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) and closely held LifeCell have agreed to transfer all marketing and distribution rights to the SPY Elite system from LifeCell to Novadaq, effective Nov. 30, 2014. Under the accord, LifeCell will provide certain services during a transition period in December for a service fee equal to the approximate revenue... [Read more of this brief]


Roth names John Chambers as vice chairman

Roth names John Chambers as vice chairman

Roth Capital Partners has named John Chambers as vice chairman in addition to his ongoing role as head of healthcare investment banking, a position he has held since joining Roth 2009. Mr. Chambers and his team has assisted Roth’s healthcare clients in raising over $8-billion in approximately 220 transactions since 2009. “John is an asset to our... [Read more of this brief]


BiondVax gets patent approvals in EU and Japan

BiondVax gets patent approvals in EU and Japan

BiondVax Pharmaceuticals (TASE:BNDX), which is developing a universal flu vaccine, has received approvals from the European Union and from Japan’s patent authorities for its patent on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines family. The patent family covers vaccination against influenza in humans and specifically, vaccines that... [Read more of this brief]


Knight invests $30-million in Teralys fund


Knight invests $30-million in Teralys fund


Knight Therapeutics (TSX:GUD) has invested $30-million into Teralys Capital Innovation Fund, which is managed by Teralys Capital. Teralys is the largest venture capital fund manager dedicated to technologies and life sciences in Canada, with $1.3-billion in assets under management and a significant focus on the North American life sciences sector. Knight... [Read more of this brief]


Leerink starts Dermira at outperform

Leerink starts Dermira at outperform

Leerink Partners has initiated coverage of Dermira (NASDAQ:DERM) with an “outperform” rating and a $32 price target based on a discounted cash flow analysis. The stock closed at $15.50 on Monday. Dermira is a development stage specialty pharmaceutical company focused exclusively on advancing therapeutics used by dermatologists to treat skin-related... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+